Active Biotech AB Interim report January – June 2016

LUND, Sweden, Aug. 11, 2016 (GLOBE NEWSWIRE) --


  • The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
  • The study results from both the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study ARPEGGIO, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the first half of 2017
  • Positive results concerning laquinimod were presented at the 68th AAN Annual Meeting (American Academy of Neurology), held in Vancouver, Canada, on April 15-21, 2016


  • The complete study results of the Phase 3 10TASQ10 study have been published in the Journal of Clinical Oncology
  • Out-licensing activities are continuing

ANYARA, Paquinimod (57-57) and SILC (ISI)

  • Out-licensing activities are continuing

Financial summary

SEK M  Q2   Q1-Q2Full Year
Net sales3.
Operating loss-14.5-70.1-30.6-127.5-177.9
Loss for the period-15.5-71.4-32.3-129.3-193.5
Loss per share, before and after dilution (SEK)-0.17-0.79-0.36-1.44-2.15
Cash and cash equivalents (at the end of the period)  57.4186.6103.6
  • Refocusing of the company is completed, operating costs reduced by 71% (SEK 95.2 M) compared with 2015
  • The number of employees will be reduced from 56 (June 2015) to 17 by the end of the third quarter of 2016
  • Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017

For further information, please contact:     

  Tomas Leanderson, President and CEO
  Tel: +46 46 19 20 95


  Hans Kolam, CFO
  Tel: +46 46 19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 05


The report is also available at

Active Biotech AB (publ) Interim Report January - June 2016